ArticlemBio2025
Genome-wide mapping of EBV-induced genomic variations identifies the role of MUC19 in EBV latency.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Omics-Level Approaches to Studying Gammaherpesvirus Infection.Pathogens (Basel, Switzerland) · 2026Review
- The Role of Mucins in Esophageal Inflammatory Diseases.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Epstein-Barr virus (EBV) infects over 95% of the world's population and is tightly associated with multiple human malignant diseases. As the first discovered human oncovirus, EBV is known to induce genomic instability by promoting various types of genomic modifications in host chromosomes. However, the mechanisms through which EBV interacts with the host genome and regulates cellular gene expression in genomic modifications are not yet fully elucidated. In this study, we conducted primary EBV infection in B cells and performed the analyses of copy number variants using whole genome sequencing. The results showed genomic regions susceptible to EBV-induced mutations and unveiled MUC19 to be a critical host factor in EBV latency, which was distinctively activated transcriptionally upon EBV infection. Finally, we identified the intrinsic tandem repeats in MUC19 to be its functional domain, which promotes cell survival and cell cycle through activating mechanistic target of rapamycin (mTOR) signaling in EBV-positive cells. Further results indicate that EBV nuclear antigen 1 binds to the promoter of the MUC19 gene and enhances its expression. In conclusion, these results provide novel insights into the roles of MUC19 in EBV latency, highlighting its potential as a promising therapeutic target for the treatment of EBV-associated lymphomas.IMPORTANCEGenomic instability is a hallmark of cancer. EBV contributes to host genomic instability after primary infection. This study maps the EBV-induced genomic variations using deep whole genome sequencing and identifies the critical factor MUC19, which is one of the most understudied genes, with a genomic sequence exceeding 177 kbp that encodes a protein over 800 kD. In this study, we revealed that EBV induced the duplicated copy number variants of the MUC19 gene and enhanced its expression, which further promotes cell survival and cell cycle via mTOR signaling. Overall, this study maps the genomic perturbations induced by EBV primary infection and offers new insights into the critical role of MUC19 in EBV latency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.